Format

Send to

Choose Destination
J Infect Dis. 2008 Jun 1;197(11):1519-22. doi: 10.1086/587942.

Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis.

Author information

1
Institute for Infectious Diseases, University of Bern, Switzerland.

Abstract

Treatment of bacterial meningitis caused by Streptococcus pneumoniae is increasingly difficult, because of emerging resistance to antibiotics. Recombinant Cpl-1, a phage lysin specific for S. pneumoniae, was evaluated for antimicrobial therapy in experimental pneumococcal meningitis using infant Wistar rats. A single intracisternal injection (20 mg/kg) of Cpl-1 resulted in a rapid (within 30 min) decrease in pneumococci in cerebrospinal fluid (CSF) by 3 orders of magnitude lasting for 2 h. Intraperitoneal administration of Cpl-1 (200 mg/kg) led to an antibacterial effect in CSF of 2 orders of magnitude for 3 h. Cpl-1 may hold promise as an alternative treatment option in pneumococcal meningitis.

PMID:
18471063
DOI:
10.1086/587942
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center